Berry DA, Ueno NT, Johnson MM, Lei X, Caputo J, Smith DA, Yancey LJ, Crump M, Stadtmauer EA, Biron P et al (2011) High-dose chemotherapy with autologous hematopoietic stem-cell transplantation in metastatic breast cancer: overview of six randomized trials. J Clin Oncol: Off J Am Soc Clin Oncol 29(24):3224–3231

Article  Google Scholar 

Sikov WM, Berry DA, Perou CM, Singh B, Cirrincione CT, Tolaney SM, Kuzma CS, Pluard TJ, Somlo G, Port ER et al (2015) Impact of the addition of carboplatin and/or bevacizumab to neoadjuvant once-per-week paclitaxel followed by dose-dense doxorubicin and cyclophosphamide on pathologic complete response rates in stage II to III triple-negative breast cancer: CALGB 40603 (Alliance). J Clin Oncol: Off J Am Soc Clin Oncol 33(1):13–21

Article  CAS  Google Scholar 

Brewster AM, Chavez-MacGregor M, Brown P (2014) Epidemiology, biology, and treatment of triple-negative breast cancer in women of African ancestry. Lancet Oncol 15(13):e625–e634

Article  PubMed  PubMed Central  Google Scholar 

Shin VY, Chen J, Cheuk IW, Siu MT, Ho CW, Wang X, Jin H, Kwong A (2019) Long non-coding RNA NEAT1 confers oncogenic role in triple-negative breast cancer through modulating chemoresistance and cancer stemness. Cell Death Dis 10(4):270

Article  PubMed  PubMed Central  Google Scholar 

Dent R, Trudeau M, Pritchard KI, Hanna WM, Kahn HK, Sawka CA, Lickley LA, Rawlinson E, Sun P, Narod SA (2007) Triple-negative breast cancer: clinical features and patterns of recurrence. Clin Cancer Res: An Off J Am Assoc Cancer Res 13(15 Pt 1):4429–4434

Article  Google Scholar 

Haffty BG, Yang Q, Reiss M, Kearney T, Higgins SA, Weidhaas J, Harris L, Hait W, Toppmeyer D (2006) Locoregional relapse and distant metastasis in conservatively managed triple negative early-stage breast cancer. J Clin Oncol: Off J Am Soc Clin Oncol 24(36):5652–5657

Article  Google Scholar 

Lehmann BD, Bauer JA, Chen X, Sanders ME, Chakravarthy AB, Shyr Y, Pietenpol JA (2011) Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies. J Clin Investig 121(7):2750–2767

Article  CAS  PubMed  PubMed Central  Google Scholar 

Mittendorf EA, Philips AV, Meric-Bernstam F, Qiao N, Wu Y, Harrington S, Su X, Wang Y, Gonzalez-Angulo AM, Akcakanat A et al (2014) PD-L1 expression in triple-negative breast cancer. Cancer Immunol Res 2(4):361–370

Article  CAS  PubMed  PubMed Central  Google Scholar 

Miklossy G, Hilliard TS, Turkson J (2013) Therapeutic modulators of STAT signalling for human diseases. Nat Rev Drug Discovery 12(8):611–629

Article  CAS  PubMed  Google Scholar 

Tong L, Li J, Li Q, Wang X, Medikonda R, Zhao T, Li T, Ma H, Yi L, Liu P et al (2020) ACT001 reduces the expression of PD-L1 by inhibiting the phosphorylation of STAT3 in glioblastoma. Theranostics 10(13):5943–5956

Article  CAS  PubMed  PubMed Central  Google Scholar 

Marzec M, Zhang Q, Goradia A, Raghunath PN, Liu X, Paessler M, Wang HY, Wysocka M, Cheng M, Ruggeri BA, Wasik MA (2008) Oncogenic kinase NPM/ALK induces through STAT3 expression of immunosuppressive protein CD274 (PD-L1, B7–H1). Proc Natl Acad Sci USA 105(52):20852–20857

Article  CAS  PubMed  PubMed Central  Google Scholar 

Meng Z, Zhang R, Wu X, Zhang M, Jin T (2022) PD-L1 mediates triple-negative breast cancer evolution via the regulation of TAM/M2 polarization. Int J Oncol. https://doi.org/10.3892/ijo.2022.5440

Article  PubMed  PubMed Central  Google Scholar 

Sullivan NJ, Sasser AK, Axel AE, Vesuna F, Raman V, Ramirez N, Oberyszyn TM, Hall BM (2009) Interleukin-6 induces an epithelial-mesenchymal transition phenotype in human breast cancer cells. Oncogene 28(33):2940–2947

Article  CAS  PubMed  PubMed Central  Google Scholar 

Chiang HC, Wang JJ, Wu RT (1992) Immunomodulating effects of the hydrolysis products of formosanin C and beta-ecdysone from Paris formosana Hayata. Anticancer Res 12(5):1475–1478

CAS  PubMed  Google Scholar 

Wu RT, Chiang HC, Fu WC, Chien KY, Chung YM, Horng LY (1990) Formosanin-C, an immunomodulator with antitumor activity. Int J Immunopharmacol 12(7):777–786

Article  CAS  PubMed  Google Scholar 

Li Y, Man S, Li J, Chai H, Fan W, Liu Z, Gao W (2014) The antitumor effect of formosanin C on HepG2 cell as revealed by 1H-NMR based metabolic profiling. Chem Biol Interact 220:193–199

Article  CAS  PubMed  Google Scholar 

Chen HC, Tang HH, Hsu WH, Wu SY, Cheng WH, Wang BY, Su CL (2022) Vulnerability of triple-negative breast cancer to Saponin Formosanin C-Induced Ferroptosis. Antioxidants (Basel) 11(2):298

Article  CAS  PubMed  Google Scholar 

Lu J, Xu F, Rao C, Shen C, Jin J, Zhu Z, Wang C, Li Q (2022) Mechanism of action of paclitaxel for treating glioblastoma based on single-cell RNA sequencing data and network pharmacology. Front Pharmacol 13:1076958

Article  CAS  PubMed  PubMed Central  Google Scholar 

Trott O, Olson AJ (2010) AutoDock Vina: improving the speed and accuracy of docking with a new scoring function, efficient optimization, and multithreading. J Comput Chem 31(2):455–461

Article  CAS  PubMed  PubMed Central  Google Scholar 

Duffield JS (2016) Beyond EMT: Epithelial STAT3 as a central regulator of fibrogenesis. J Am Soc Nephrol 27(12):3502–3504

Article  CAS  PubMed  PubMed Central  Google Scholar 

Li J, Wu Z, Chen G, Wang X, Zhu X, Zhang Y, Zhang R, Wu W, Zhu Y, Ma L, Yu H (2023) Formosanin C inhibits non-small-cell lung cancer progression by blocking MCT4/CD147-mediated lactate export. Phytomedicine 109:154618

Article  CAS  PubMed  Google Scholar 

Chu ML, Lin PW, Liu YW, Wu SY, Lan SH, Su CL, Liu HS (2023) Formosanin C suppresses cancer cell proliferation and migration by impeding autophagy machinery. Kaohsiung J Med Sci 39(5):489–500

Article  CAS  PubMed  Google Scholar 

Lin PL, Tang HH, Wu SY, Shaw NS, Su CL (2020) Saponin Formosanin C-induced ferritinophagy and ferroptosis in human hepatocellular carcinoma cells. Antioxidants (Basel) 9(8):682

Article  CAS  PubMed  Google Scholar 

Fan L, Li Y, Sun Y, Yue Z, Meng J, Zhang X, Zhang R, Zhang D, Zhang F, Mei Q (2015) Paris saponin VII inhibits metastasis by modulating matrix metalloproteinases in colorectal cancer cells. Mol Med Rep 11(1):705–711

Article  CAS  PubMed  Google Scholar 

Yang M, Zou J, Zhu H, Liu S, Wang H, Bai P, Xiao X (2015) Paris saponin II inhibits human ovarian cancer cell-induced angiogenesis by modulating NF-κB signaling. Oncol Rep 33(5):2190–2198

Article  CAS  PubMed  Google Scholar 

Chen M, Ye K, Zhang B, Xin Q, Li P, Kong AN, Wen X, Yang J (2019) Paris Saponin II inhibits colorectal carcinogenesis by regulating mitochondrial fission and NF-κB pathway. Pharmacol Res 139:273–285

Article  CAS  PubMed  Google Scholar 

Man S, Lv P, Cui J, Liu F, Peng L, Ma L, Liu C, Gao W (2020) Paris saponin II-induced paraptosis-associated cell death increased the sensitivity of cisplatin. Toxicol Appl Pharmacol 406:115206

Article  CAS  PubMed  Google Scholar 

Marotta LL, Almendro V, Marusyk A, Shipitsin M, Schemme J, Walker SR, Bloushtain-Qimron N, Kim JJ, Choudhury SA, Maruyama R et al (2011) The JAK2/STAT3 signaling pathway is required for growth of CD44⁺CD24⁻ stem cell-like breast cancer cells in human tumors. J Clin Investig 121(7):2723–2735

Article  CAS  PubMed  PubMed Central  Google Scholar 

Chang Q, Bournazou E, Sansone P, Berishaj M, Gao SP, Daly L, Wels J, Theilen T, Granitto S, Zhang X et al (2013) The IL-6/JAK/Stat3 feed-forward loop drives tumorigenesis and metastasis. Neoplasia 15(7):848–862

Article  CAS  PubMed  PubMed Central